Does the industry no longer need medical representatives? The sound comes from these four categories of people.

With the arrival of the second batch of national picks, the network for the industry also need not need medicine representatives on this topic, and began to change more, today Dami saw an interesting statement from the Japanese industrySmall partners know that Japan's health policy and market environment in recent years is a bit similar to our domestic, and recently because of the epidemic and we are in a common situation, coupled with this period of time each year, the industry will publish statistics on the number of medical representativesTherefore, the medical representative small partners are also discussing this topicFirst, as mature medicines are affected by the price of medicines brought about by health policies and health insurance payments, it is inevitable that the number of pharmaceutical representatives will decrease, as is the case in many countries, but the industry can never need a medical representativeWhere does the industry come from without the need for medical representatives? Today, there are japan's small partners listed the following 4 categories of people: have been a medical representative, but for various reasons to withdraw the original representative; still do medical representatives, but the work is not smooth; envy the medical representatives of the treatment of good people, or did not have the opportunity to be representatives of the outsider; in order to attract attention, create panic media people haha, take these comparisons to our side, is there a similar place? You know, a lot of medical information on the network is written by outsiders, or just from a single location to see the industry prospects, the vision is very limited, although this information for senior medical practitioners, do not think, but for some of the new people soon into the industry, or easy to cause panic, from some message feedback can be seenIn fact, there is also a common argument that IT technology development is very strong, the future does not need to represent the transmission of information, this is not possible, the first two years have been said that the future does not need a doctor, AI can be diagnosed, prescription or even surgery, this logic can also be put on the pharmacist, but, a little bit of thinking also know impossible, from ancient times, technology is a tool, but also people to useFrom the clouds of the past few months of the epidemic, we already know that there is no solid work on the line, online communication and visits just take it for grantedBut online visits to these new environments are indeed needed in the future, and perhaps the industry doesn't need the old-time medical representatives, who still have strong demand for new-capacity medical representativesIs there any change in the current domestic medical practitioners? For the situation of the pharmaceutical natural persons to do agent for the time being, strictly say that they are not representatives of medicine, we only on the enterprise officially hired pharmaceutical representatives of employees, there are still few people left the industry, the so-called "large number of personnel loss" of the illusion, mostly in the market environment changes, the enterprise's product portfolio and future drug pipeline adjustment caused by job fluctuations, transfer and job-hopping frequently is trueFor innovative drugs, cutting off the information of pharmaceutical representatives is tantamount to cutting off the lifeline of pharmaceutical companies, we can see that many of the new drugs in the outbreak of the promotion of the state is at a standstillWithout medical representation, how can we quickly advance the accumulation of clinical experience in innovative drugs, and how can clinical trial data be transmitted quickly? In today's rapid development of individualized and innovative therapies such as gene therapy and cell therapy, doctors are afraid to use newly marketed drugs without dataBut with the promotion of volume procurement, it is inevitable that the number of representative positions responsible for mature medicines will become less and will lead to increased turnover over the next two years, and that companies will take into account labor costs and provide high-paying senior representative positions that do not match their value, and enterprises will be affected by the transfer of low-paying and easy-to-develop new capabilities of young people, as in Japan, where pharmaceutical representatives have been slowly declining over the past two years, a cumulative reduction of more than 5,000Most of the lost are old delegates in their 40s and 50s who left their posts in the form of early retirementTherefore, in the past, enterprises will reconsider the functions and size of medical representatives, re-evaluate the current team of medical representatives, redesign the training and assessment system, it is inevitableThe most important thing to consider is whether you will be left behind when the number of delegates in the industry's demand decreases.